Obesity is a medical condition characterized by the excessive amount of fat. It can lead to many diseases such as cardiovascular, diabetes, and others. It can be treated via a combination of exercise and medication. Market Research Future (MRFR) has collected information on the causes of obesity, developments in its treatment, and medications and its prospects for the period between 2017 to 2023 (forecast period).
The global obesity treatment market is set to expand at a CAGR of 16.7% CAGR during the forecast period. The number of patients diagnosed with obesity and the acceptance of bariatric surgeries are factors driving the market growth. For instance, the Monash University has accounted for close to 15,000 bariatric surgeries occurring in Australia in 2015.
Rising demand for minimally invasive surgeries, awareness of the health risks posed by obesity, and favorable reimbursement policies are major growth drivers of the market. Balloon capsules are a brand-new method for losing weight and not being diagnosed with other medical conditions. The large number of endoscopic surgeries being conducted globally is an indicator of the upward trend of the global obesity treatment market.
But high costs of surgeries and low healthcare expenditure in developing economies can impede the global obesity treatment market growth.
Competitive Analysis
Leading players in the global obesity treatment market include Olympus Corporation, Covidien plc, Mediflex Surgical Products, USGI Medical Inc., Medtronic, Johnson & Johnson Services Inc., EnteroMedics Inc., Cousin Biotech, Allergan, Orexigen Therapeutics Inc., Novo Nordisk A/S, F. Hoffman-La Roche Ltd., Arena Pharmaceuticals Inc., and VIVUS Inc.
Research projects are likely to be highly important for players in the global obesity treatment market in the coming years. Development and commercialization of more efficient and noninvasive obesity treatments is likely to remain a promising avenue for players in the global obesity treatment market. Increasing research into genetics is also likely to play a key role in the development of the obesity treatment market over the forecast period.
Segmentation
The global obesity treatment market has been studied by MRFR on the basis of a Type, Diagnosis, Treatment, and End-user. These segments and data in them are expected to facilitate the decision-making process for the future.
- By Type, the obesity treatment market has been studied on the basis of food obesity, anxiety obesity, inactivity obesity, atherogenic obesity, venous obesity, and gluten obesity.
- By Diagnosis, the report containing details of the obesity treatment market has been segmented into physical examination, blood tests, and others. The blood tests segment includes thyroid test, liver function test, cholesterol test, and others. The physical examination segment comprises blood pressure measurement, heart rate measurement, and others.
- By Treatment, the study on the global obesity treatment market includes surgery, medication, lifestyle changes, and others. The medication segment has been studied on the basis of lorcaserin, orlistat, liraglutide, phentermine and topiramate, and others. The surgery segment includes Laparoscopic Adjustable Gastric Banding (LAGB), gastric bypass surgery, biliopancreatic diversion, gastric sleeve, gastric sleeve, and others.
- By End-user, the report on the obesity treatment market includes clinics, pharmacies, hospitals, and others.
Regional Analysis
The Middle East & Africa (MEA), Americas, Asia Pacific (APAC), and Europe are regions which have become the focus of interest in the global obesity treatment market report.
The Americas are predicted to dominate the global obesity treatment market till the end of the forecast period owing to a large obese population. The large numbers of young people in the United States with a BMI over 35 is indicative of the large growth potential of the market within the region. Endoscopic procedures and obesity management procedures can bode well for the market. Recently, Stanford Children’s Health experts have created weight management programs for children for maintaining their weight without going exceeding it.
Europe is the second-largest region of the market due to large availability of funds, large obese population, and large number of bariatric surgeries. As per the Eurostat report of 2016, more than 51.6% of adults living in the European Union are defined to be overweight. The National Institute of Health Research, a government agency in the U.K. has been awarded close to USD 647,832.50 for checking on the efficacy of obesity management programs by the NHS.
